Cartesian Therapeutics (RNAC) Total Non-Current Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Total Non-Current Liabilities data on file, last reported at $436.5 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $436.5 million, up 1.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $436.5 million (up 1.29% YoY), and the FY2025 annual result was $422.5 million, down 3.53% from the prior year.
• Total Non-Current Liabilities improved to $436.5 million in Q1 2026 per RNAC's latest filing, from $422.5 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $454.6 million in Q3 2024 and troughed at $32.6 million in Q3 2023.
• A 5-year average of $278.0 million and a median of $407.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities slumped 58.94% in 2022, then jumped 1293.77% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $52.9 million in 2022, then soared by 728.24% to $438.3 million in 2023, then dropped by 0.07% to $438.0 million in 2024, then retreated by 3.53% to $422.5 million in 2025, then gained by 3.3% to $436.5 million in 2026.
• Business Quant data shows RNAC's Total Non-Current Liabilities at $436.5 million in Q1 2026, $422.5 million in Q4 2025, and $407.7 million in Q3 2025.